Pfizer (NYSE:PFE) appears to be likely to be the first drugmaker, along with its partner BioNTech (NASDAQ:BNTX), to win U.S. emergency use authorization (EUA) for a coronavirus vaccine. AstraZeneca (NASDAQ:AZN), with plans to produce up to 3 billion doses next year, might distribute more doses of its COVID-19 vaccine globally […]